The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jan 8

PMID 36613695

Authors

Vinicio Carloni

Elisa Morganti

Andrea Galli

Antonio Mazzocca

Affiliations

Soon will be listed here.

Abstract

Variation in chromosome structure is a central source of DNA damage and DNA damage response, together representinga major hallmark of chromosomal instability. Cancer cells under selective pressure of therapy use DNA damage and DNA damage response to produce newfunctional assets as an evolutionary mechanism. Recent efforts to understand DNA damage/chromosomal instability and elucidate its role in initiation or progression of cancer have also disclosed its vulnerabilities represented by inappropriate DNA damage response, chromatin changes, andinflammation. Understanding these vulnerabilities can provide important clues for predicting treatment response and for the development of novel strategies that prevent the emergence of therapy resistant tumors.

Citing Articles

Molecular mechanisms of aging and anti-aging strategies.

Li Y, Tian X, Luo J, Bao T, Wang S, Wu X Cell Commun Signal. 2024; 22(1):285.

PMID: 38790068 PMC: 11118732. DOI: 10.1186/s12964-024-01663-1.

References

Unterholzner L, Keating S, Baran M, Horan K, Jensen S, Sharma S . IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010; 11(11):997-1004. PMC: 3142795. DOI: 10.1038/ni.1932. View

Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M . DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. Cell. 2018; 173(4):972-988.e23. PMC: 8108093. DOI: 10.1016/j.cell.2018.03.050. View

Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B . PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol. 2009; 19(6):524-9. PMC: 2750839. DOI: 10.1016/j.cub.2009.02.018. View

Dev H, Chiang T, Lescale C, de Krijger I, Martin A, Pilger D . Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol. 2018; 20(8):954-965. PMC: 6145444. DOI: 10.1038/s41556-018-0140-1. View

Lord C, Ashworth A . BRCAness revisited. Nat Rev Cancer. 2016; 16(2):110-20. DOI: 10.1038/nrc.2015.21. View

Zitvogel L, Kepp O, Kroemer G . Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011; 8(3):151-60. DOI: 10.1038/nrclinonc.2010.223. View

Burma S, Chen B, Murphy M, Kurimasa A, Chen D . ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001; 276(45):42462-7. DOI: 10.1074/jbc.C100466200. View

Xie A, Hartlerode A, Stucki M, Odate S, Puget N, Kwok A . Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell. 2007; 28(6):1045-57. PMC: 2275782. DOI: 10.1016/j.molcel.2007.12.005. View

Schuster-Bockler B, Lehner B . Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature. 2012; 488(7412):504-7. DOI: 10.1038/nature11273. View

10.

Bakhoum S, Kabeche L, Compton D, Powell S, Bastians H . Mitotic DNA Damage Response: At the Crossroads of Structural and Numerical Cancer Chromosome Instabilities. Trends Cancer. 2017; 3(3):225-234. PMC: 5518619. DOI: 10.1016/j.trecan.2017.02.001. View

11.

Syed A, Tainer J . The MRE11-RAD50-NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair. Annu Rev Biochem. 2018; 87:263-294. PMC: 6076887. DOI: 10.1146/annurev-biochem-062917-012415. View

12.

Janssen A, Kops G, Medema R . Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A. 2009; 106(45):19108-13. PMC: 2776415. DOI: 10.1073/pnas.0904343106. View

13.

Sotillo R, Schvartzman J, Socci N, Benezra R . Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature. 2010; 464(7287):436-40. PMC: 2841716. DOI: 10.1038/nature08803. View

14.

Schwarz J, Lovly C, Piwnica-Worms H . Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res. 2003; 1(8):598-609. View

15.

Lulli M, Del Coco L, Mello T, Sukowati C, Madiai S, Gragnani L . DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer. Cancer Res. 2021; 81(11):2861-2873. DOI: 10.1158/0008-5472.CAN-20-3134. View

16.

Birkbak N, Eklund A, Li Q, McClelland S, Endesfelder D, Tan P . Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011; 71(10):3447-52. PMC: 3096721. DOI: 10.1158/0008-5472.CAN-10-3667. View

17.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

18.

Brenner J, Feng F, Han S, Patel S, Goyal S, Bou-Maroun L . PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-13. PMC: 3319786. DOI: 10.1158/0008-5472.CAN-11-3648. View

19.

Falck J, Coates J, Jackson S . Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005; 434(7033):605-11. DOI: 10.1038/nature03442. View

20.

Heijink A, Talens F, Jae L, van Gijn S, Fehrmann R, Brummelkamp T . BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat Commun. 2019; 10(1):100. PMC: 6327059. DOI: 10.1038/s41467-018-07927-y. View